Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection.
Cassano
Nicoletta
N
Vena
Gino A
GA
D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D000068800:Etanercept; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000175:diagnosis*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy; D008111:Liver Function Tests; D008297:Male; D007690:Polycystic Kidney Diseases / Q000150:complications / Q000175:diagnosis; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D006435:Renal Dialysis / Q000379:methods*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D016572:Cyclosporine; D000068800:Etanercept